Laurion Capital Management LP Acquires Shares of 19,823 Ultragenyx Pharmaceutical Inc (RARE)

Laurion Capital Management LP acquired a new position in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) in the 1st quarter, Holdings Channel reports. The fund acquired 19,823 shares of the biopharmaceutical company’s stock, valued at approximately $1,375,000.

Several other large investors also recently bought and sold shares of RARE. Exane Derivatives purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $36,000. Meeder Asset Management Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 321.1% during the first quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 456 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Ultragenyx Pharmaceutical by 100.9% during the fourth quarter. Bank of Montreal Can now owns 1,079 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 542 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $55,000. Finally, First Mercantile Trust Co. raised its holdings in shares of Ultragenyx Pharmaceutical by 101.0% during the first quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 495 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Several research analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $77.00 target price (down previously from $88.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 7th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, April 26th. Morgan Stanley raised shares of Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $68.00 to $83.00 in a report on Wednesday, March 27th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $73.00 target price for the company in a report on Tuesday, April 23rd. Finally, SunTrust Banks raised their target price on shares of Ultragenyx Pharmaceutical to $71.00 and gave the stock a “buy” rating in a report on Wednesday, January 23rd. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $78.65.



RARE opened at $58.57 on Thursday. Ultragenyx Pharmaceutical Inc has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.77 and a quick ratio of 11.60. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of -7.93 and a beta of 2.14.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 550.30% and a negative return on equity of 51.00%. The firm had revenue of $18.17 million during the quarter, compared to analysts’ expectations of $18.75 million. During the same period in the previous year, the firm posted $0.63 EPS. The firm’s quarterly revenue was up 70.1% on a year-over-year basis. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc will post -6.99 EPS for the current year.

In other news, EVP Karah Herdman Parschauer sold 468 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $68.30, for a total transaction of $31,964.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shalini Sharp sold 14,800 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $70.00, for a total transaction of $1,036,000.00. The disclosure for this sale can be found here. 8.40% of the stock is owned by insiders.

WARNING: This news story was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://dakotafinancialnews.com/2019/05/23/laurion-capital-management-lp-acquires-shares-of-19823-ultragenyx-pharmaceutical-inc-rare.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Article: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.